Pdufa dates are also set for Sarepta and UCB, and panels will discuss Leqembi and Beyfortus.
Aside from Seagen, small takeouts dominate the first quarter.
A welcome return of shareholder activism sees a curious battle develop for the one-hit wonder Exelixis.
After Cabometyx’s latest clinical setback Exelixis might have to turn to follow-on projects for future growth.
Ferring's Adstiladrin has joined Keytruda with a US approval, but it might not be the answer doctors are looking for.
With interest rates rising and developers focusing on favourite therapy areas, should hopes for mega-deals be reined in?
December’s $28bn takeout of Horizon bumps 2022’s M&A numbers to respectable levels.
Takeouts of Cincor, Albireo and Amryt emerge with contingent payment terms, as biopharma buyers flex their muscles.